Read by QxMD icon Read

ESMO guideline

Rosa Giuliani, Josep Tabernero, Fatima Cardoso, Keith Hanson McGregor, Malvika Vyas, Elisabeth G E de Vries
Background: Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current level of knowledge, understanding and comfort of use of biosimilars among prescribers specialised in oncology. Methods: A 19-question survey was developed using the SurveyMonkey online platform (https://www...
2019: ESMO Open
Katarzyna Winter, Renata Talar-Wojnarowska, Andrzej Dąbrowski, Małgorzata Degowska, Marek Durlik, Anita Gąsiorowska, Stanisław Głuszek, Grażyna Jurkowska, Aleksandra Kaczka, Paweł Lampe, Tomasz Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Grażyna Rydzewska, Janusz Strzelczyk, Zbigniew Śledziński, Ewa Małecka-Panas
These recommendations refer to the current management in pancreatic ductal adenocarcinoma (PDAC), a neoplasia characterised by an aggressive course and extremely poor prognosis. The recommendations regard diagnosis, surgical, adjuvant and palliative treatment, with consideration given to endoscopic and surgical methods. A vast majority of the statements are based on data obtained in clinical studies and experts' recommendations on PDAC management, including the following guidelines: International Association of Pancreatology/European Pancreatic Club (IAP/EPC), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and Polish Society of Gastroenterology (PSG) and The National Institute for Health and Care Excellence (NICE) ...
2019: Przegla̜d Gastroenterologiczny
Stina Garvin, Eva Vikhe Patil, Lars-Gunnar Arnesson, Husam Oda, Elham Hedayati, Annelie Lindström, Ivan Shabo
Breast cancer (BC) intrinsic subtype classification is based on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation marker Ki-67. The expression of these markers depends on both the genetic background of the cancer cells and the surrounding tumor microenvironment. In this study, we explore macrophage traits in cancer cells and intra-tumoral M2-macrophage infiltration (MI) in relation to intrinsic subtypes in non-metastatic invasive BC treated with breast conserving surgery, with and without postoperative radiotherapy (RT)...
March 26, 2019: Virchows Archiv: An International Journal of Pathology
Corentin Delhaye, Alain Hendlisz, Michael Vouche
PURPOSE OF REVIEW: This review explores current knowledge and recent data about vascular-centered locoregional treatments and proposes alternate algorithms. RECENT FINDINGS: Hepatocellular carcinoma represents the sixth most common neoplasm worldwide. Currently, the Barcelona Clinic Liver Cancer (BCLC) staging is the most commonly used in Europe for treatment allocation. According to this classification, European Society for Medical Oncology (ESMO) guidelines currently recommend transarterial chemoembolization for intermediate stage HCC and systemic treatments, such as, sorafenib in more advanced stages...
March 20, 2019: Current Opinion in Oncology
Ciara Ellen Gibbons, Cecily Mary Quinn, David Gibbons
CONTEXT: Fine-needle aspiration biopsy (FNAB) is frequently used to stage the axilla preoperatively in patients with primary breast carcinoma. In the light of the ACOSOG-Z0011 and AMAROS trials that specified sentinel lymph node biopsy as an inclusion criterion, the role of FNAB in axillary staging is changing. OBJECTIVE: This article will review the diagnostic accuracy of FNAB in staging of the axilla in patients with primary breast carcinoma. The efficacy of axillary FNAB compared with core-needle biopsy will be evaluated...
March 20, 2019: Acta Cytologica
Osamah A Hakami, Julia Ioana, Shahzad Ahmad, Tommy Kyaw Tun, Seamus Sreenan, John H McDermott
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other solid tumours. Immune-related adverse events (irAEs) including endocrinopathies have been well described with this and other PD-1 inhibitors. While hypothyroidism and hyperthyroidism, and less commonly hypophysitis, are the most common endocrinopathies occurring in patients treated with pembrolizumab, the incidence of type 1 diabetes mellitus (T1DM) was low in clinical trials...
March 5, 2019: Endocrinology, Diabetes & Metabolism Case Reports
Xichun Hu, Ting Li, Biyun Wang, Jian Zhang, Xiaoli Yu, Zhimin Shao
The primary aim of the international advance breast cancer (ABC) guidelines are to guide treatment decisions in many different healthcare settings, but need adaptations due to different access to care. These guidelines are based on the most up-to-date evidence. However, Chinese experts have a different national condition and policies to face. The Chinese Anti-Cancer Association Committee of Breast Cancer Society guideline (CBCS guideline) is to guide treatments and to reflect unmet needs of Chinese breast cancer patients...
February 22, 2019: Breast: Official Journal of the European Society of Mastology
Bernard Escudier, Camillo Porta, Manuela Schmidinger, Nathalie Rioux-Leclercq, Axel Bex, Vincent Khoo, Viktor Grünwald, Silke Gillessen, Alan Horwich
No abstract text is available yet for this article.
February 21, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Pascale Dielenseger, Sussanne Börjeson, Cheryl Vidall, Annie Young, Patrick Jahn
INTRODUCTION: Preventing CINV is possible when guideline-recommended antiemetics are used. Because oncology nurses play a critical role in risk assessment and management of CINV, a survey of European nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence. METHODS: From March 2016 to Feb 2017, 212 oncology nurses in 16 European countries completed a 20-question online survey...
February 19, 2019: Supportive Care in Cancer
Giorgio Bogani, Maria Teresa Ricci, Marco Vitellaro, Antonino Ditto, Valentina Chiappa, Francesco Raspagliesi
OBJECTIVE: Lynch syndrome is a risk factor for developing endometrial carcinoma. Our aim was to evaluate the impact of gene-specific germline pathogenic variants on clinical features of patients affected by endometrial cancer. METHODS: Patients with a diagnosis of endometrial cancer and with a germline pathogenic variant in mismatch repair genes were reviewed. Patients were classified on the basis of classes of risk according to the ESGO-ESGO-ESTRO (European Society of Medical Oncology/European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology) guidelines...
February 16, 2019: International Journal of Gynecological Cancer
A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro, P Schirmacher, C Verslype, C J Zech, D Arnold, E Martinelli
No abstract text is available yet for this article.
January 31, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann, S Peters
No abstract text is available yet for this article.
January 30, 2019: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Steffen Böhm, Nhu Le, Michelle Lockley, Elly Brockbank, Asma Faruqi, Ian Said, Arjun Jeyarajah, Rekha Wuntakal, Blake Gilks, Naveena Singh
OBJECTIVE: The Chemotherapy Response Scoring (CRS) system was developed to enable reproducible reporting of histologic tumor response in interval debulking specimens following neoadjuvant chemotherapy in advanced stage tubo-ovarian high-grade serous carcinoma. This prognostic biomarker has been included in ovarian cancer pathology reporting guidelines (International Collaboration on Cancer Reporting, College of American Pathologists) and in the upcoming European Society for Medical Oncology-European Society of Gynaecological Oncology (ESMO-ESGO) guidelines for ovarian cancer management...
January 25, 2019: International Journal of Gynecological Cancer
Maayan Fradkin, Ron Batash, Shiran Elamleh, Ronen Debi, Pamela Schaffer, Moshe Schaffer, Noam Asna
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is considered a severe side effect of therapeutic agents with limited treatment options. The incidence of CIPN in cancer patients is approximately 3-7% in cytostatic monotherapy and as high as 38% in cases of poly-chemotherapy. The prevalence of CIPN was found to be 68% within the first month of chemotherapy treatment. In some cases, CIPN can resolve, partially or completely, after completion of the treatment; in other cases, it can remain for a long time and affect the patient's quality of life...
January 7, 2019: Current Medicinal Chemistry
Erin McKenzie, Pearl Zaki, Srinivas Raman, Robert Olson, Thomas McFarlane, Carlo DeAngelis, Stephanie Chan, William Pidduck, Yasmeen Razvi, Ahmad Bushehri, Edward Chow
PURPOSE: Radiation-induced nausea and vomiting (RINV) can affect 50-80% of patients undergoing radiotherapy and negatively impacts quality of life. This review aimed to compare the most recent RINV antiemetic guidelines produced by the Multinational Association for Supportive Care in Cancer (MASCC), the European Society of Clinical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Future improvements to the guidelines and the need for further research in RINV were also discussed...
March 2019: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Y-L Wu, D Planchard, S Lu, H Sun, N Yamamoto, D-W Kim, D S W Tan, J C-H Yang, M Azrif, T Mitsudomi, K Park, R A Soo, J W C Chang, A Alip, S Peters, J-Y Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients...
December 28, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Elena Zamagni, Paola Tacchetti, Michele Cavo
Bone disease is the most frequent feature of multiple myeloma (MM) and represents a marker of end-organ damage; it is used to establish the diagnosis and to dictate the immediate need for therapy. For this reason, imaging plays a significant role in the management of MM patients. Although conventional radiography has traditionally been the standard imaging modality, its low sensitivity in detecting osteolytic lesions and inability to evaluate response to therapy has called for the use of more sophisticated techniques, such as whole-body low-dose computed tomography (WBLDCT), whole-body magnetic resonance imaging, and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT)...
February 14, 2019: Blood
Katarzyna Holub, Albert Biete
BACKGROUND: Systemic inflammation has long been related with adverse survival outcomes in cancer patients, and its biomarkers, such as the Neutrophil-to-Lymphocyte Ratio (NLR), are recognized as poor prognostic indicators. However, the role of eosinophils in this field has been largely overlooked. Here, we describe two new pre-treatment biomarkers, expressed as Eosinophil-to-Lymphocytes Ratio (ELR) and Eosinophil*Neutrophil-to-Lymphocytes ratio (ENLR), and we analyse their impact on prognosis of endometrial cancer (EC) patients...
December 22, 2018: BMC Cancer
Daniela de Freitas, Fernando Nalesso Aguiar, Cristina Anton, Carlos Eduardo Bacchi, Jesus Paula Carvalho, Filomena Marino Carvalho
BACKGROUND: Risk stratification of endometrial carcinomas is primarily based on surgical staging that requires extensive retroperitoneal lymph node dissection. One of the most powerful predictor of lymph node involvement is the lymph vascular space invasion (LVSI). The objective of this study was to determine the potential of L1 Cell Adhesion Molecule (L1CAM) to predict LVSI and its association with other risk factors in endometrioid endometrial carcinomas. MATERIALS AND METHODS: We studied 47 consecutive patients aged 37-88 (61...
2018: PloS One
Stefan Mönig, Sander van Hootegem, Mickael Chevallay, Bas P L Wijnhoven
The incidence of esophageal and junctional cancer has been increasing in western industrialized nations in the past 30 years. At the time of diagnosis, approximately 50% of patients with esophageal and junctional cancers have distant metastases and are considered incurable. In the recent ESMO guidelines and the German S3 guidelines, surgical therapy for metastatic disease is not recommended. In spite of these recommendations, the treatment of limited metastatic (oligo-metastastic) esophagogastric cancer is currently undergoing a shift towards a more aggressive therapy...
October 2018: Best Practice & Research. Clinical Gastroenterology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"